Jazz Pharmaceuticals PLC Q3 2021 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : Renee, you talked about how, as the newly launched commercial portfolio matures and scales, that you expect to realize further operating leverage. Can you talk about if we should expect operating margin improvement in 2022 over 2021?

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : Okay. Got it. Yes. I'm just trying to figure out if next year counts as one of the years of those launch products beginning to mature or still kind of more of an investment year?

Question: Gary Jay Nachman - BMO Capital Markets Equity Research - Analyst : Could you talk about the overall reimbursement and access for Xywav? How the net pricing has been trending for the narcolepsy indication? What the initial status has been for IH? How you've been managing that? And then what might change when an AG of Xyrem is available next year? How much visibility you have on that at this point? And just one other one, if I could sneak it in. Just on Sunosi, there was a big acceleration, it seems in the third quarter. So you didn't comment on that in the prepared remarks. How much of that is net pricing versus actual demand volumes?

Question: Brandon Richard Folkes - Cantor Fitzgerald & Co., Research Division - Analyst : I just want to circle back to Xywav, the goal of having 50% of -- or more than 50% of patients on Xywav by 2023. You seem to be well on your way there. But maybe can you just talk about how dependent achieving that goal is on IH from here?